The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 8805 participants.

Also called NCT06494878

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 8,805 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06494878
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, Canada, Denmark, France, Ireland, Netherlands, Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06494878. Randomized; no masking; primary purpose prevention. Start 2026-06-04 (actual); primary completion 2030-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Condition
Venous Thromboembolism
Condition
Postpartum Period
Condition
Aspirin
Condition
Low Molecular Weight Heparin
Intervention (Drug)
Aspirin
Intervention (Drug)
Low-molecular-weight heparin
Lead sponsor
University of Calgary (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)
Collaborator
European Clinical Research Infrastructure Network (class: other)

Record details

Record id
cardio:ct-nct06494878
Content hash
5cda8c95dba6ca223dea2088e9ba62645fa370df32fea45a57b241dd9a3692c1